SLC5A2 and chronic kidney disease: To assist decision-makers in prioritizing SGLT2 inhibitors, we aimed to compare the cost-per-outcome implications of dapagliflozin and empagliflozin in patients with CKD in the presence or absence of DM based on the results of the DAPA-CKD and EMPA-KIDNEY clinical trials under a predefined budget constraint that was set by the Institute for Clinical and Economic Review (ICER) (Lin et al., 2022).